IONS logo

IONS
Ionis Pharmaceuticals Inc

6,663
Mkt Cap
$12.4B
Volume
1.66M
52W High
$86.74
52W Low
$23.95
PE Ratio
-30.46
IONS Fundamentals
Price
$75.13
Prev Close
$75.09
Open
$75.70
50D MA
$78.67
Beta
0.72
Avg. Volume
2.46M
EPS (Annual)
-$2.38
P/B
25.09
Rev/Employee
$673,117.69
$12,595.28
Loading...
Loading...
News
all
press releases
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS
Assenagon Asset Management S.A. cut its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 90.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,316 shar...
MarketBeat·2d ago
News Placeholder
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·5d ago
News Placeholder
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
Ionis Pharmaceuticals cuts Tryngolza price ahead of sHTG decision, with analysts seeing stronger sales potential and competitive positioning.read more...
Benzinga·6d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays
Barclays increased their price target on shares of Ionis Pharmaceuticals from $95.00 to $106.00 and gave the stock an "overweight" rating in a report on Thursday...
MarketBeat·7d ago
News Placeholder
What is HC Wainwright's Estimate for IONS FY2027 Earnings?
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Research analysts at HC Wainwright issued their FY2027 EPS estimates for Ionis Pharmaceuticals in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.35) pe...
MarketBeat·7d ago
News Placeholder
Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price
Needham & Company LLC raised their price objective on shares of Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a "buy" rating in a research report on Wednesday...
MarketBeat·7d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright
HC Wainwright increased their price objective on Ionis Pharmaceuticals from $110.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday...
MarketBeat·7d ago
News Placeholder
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
Zacks·8d ago
News Placeholder
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 5,812 Shares of Stock
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eugene Schneider sold 5,812 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $70.97, for a total value of $412,477.64. Following the sale, the executive vice...
MarketBeat·9d ago
<
1
2
...
>

Latest IONS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.